Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders.
SEE WHO WE ARE
Nyxol® Eye Drops is a once-daily preservative-free eye drop formulation designed to reduce pupil size and improve visual acuity.
APX3330 is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammatory pathways relevant to retinal and choroidal vascular diseases.
Ocuphire Pharma plans to readout 4 clinical trials with a potential NDA filing for the RM indication in 2022.
Aug 12, 2022 7:00am EDT
Aug 8, 2022 7:00am EDT
Aug 3, 2022 8:00am EDT
Jul 7, 2022 8:00am EDT
Stay informed and receive company updates straight to your inbox.